BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 15569994)

  • 1. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
    Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
    Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
    Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
    Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of HER2 and its association with AP-2 in breast cancer.
    Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
    Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer.
    Lengyel E; Schmalfeldt B; Konik E; Späthe K; Härting K; Fenn A; Berger U; Fridman R; Schmitt M; Prechtel D; Kuhn W
    Gynecol Oncol; 2001 Aug; 82(2):291-8. PubMed ID: 11531282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression.
    Davidson B; Konstantinovsky S; Nielsen S; Dong HP; Berner A; Vyberg M; Reich R
    Clin Cancer Res; 2004 Nov; 10(21):7335-46. PubMed ID: 15534110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A; Karameris A; Arnogiannaki N; Ardavanis A; Bassilopoulos P; Trangas T; Talieri M
    Br J Cancer; 2001 Jun; 84(11):1488-96. PubMed ID: 11384099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.
    Ignatiadis M; Xenidis N; Perraki M; Apostolaki S; Politaki E; Kafousi M; Stathopoulos EN; Stathopoulou A; Lianidou E; Chlouverakis G; Sotiriou C; Georgoulias V; Mavroudis D
    J Clin Oncol; 2007 Nov; 25(33):5194-202. PubMed ID: 17954712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
    Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
    Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma.
    Mylona E; Nomikos A; Magkou C; Kamberou M; Papassideri I; Keramopoulos A; Nakopoulou L
    Histopathology; 2007 Feb; 50(3):338-47. PubMed ID: 17257129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
    Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
    Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer.
    Sillanpää S; Anttila M; Voutilainen K; Ropponen K; Turpeenniemi-Hujanen T; Puistola U; Tammi R; Tammi M; Sironen R; Saarikoski S; Kosma VM
    Gynecol Oncol; 2007 Feb; 104(2):296-303. PubMed ID: 17034838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.
    Wang-Rodriguez J; Cross K; Gallagher S; Djahanban M; Armstrong JM; Wiedner N; Shapiro DH
    Mod Pathol; 2002 Aug; 15(8):853-61. PubMed ID: 12181271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
    Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
    Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
    Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
    Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
    Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
    Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis.
    Dolled-Filhart M; Camp RL; Kowalski DP; Smith BL; Rimm DL
    Clin Cancer Res; 2003 Feb; 9(2):594-600. PubMed ID: 12576423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
    Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
    J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinase-2 (MMP-2) and MMP-9 expression in invasive ductal carcinoma of the breast.
    Sullu Y; Demirag GG; Yildirim A; Karagoz F; Kandemir B
    Pathol Res Pract; 2011 Dec; 207(12):747-53. PubMed ID: 22030137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.